HRP20110540T1 - Antibakterijski derivati kinolina - Google Patents
Antibakterijski derivati kinolina Download PDFInfo
- Publication number
- HRP20110540T1 HRP20110540T1 HR20110540T HRP20110540T HRP20110540T1 HR P20110540 T1 HRP20110540 T1 HR P20110540T1 HR 20110540 T HR20110540 T HR 20110540T HR P20110540 T HRP20110540 T HR P20110540T HR P20110540 T1 HRP20110540 T1 HR P20110540T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- aryl
- mono
- het
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
Spoj, naznačen time, da je prikazan formulom (Ia) ili (Ib) uključujući i bilo koji njegov stereokemijski izomerni oblik, pri čemu p je cijeli broj koji je jednak 1, 2, 3 ili 4; q je cijeli broj koji je jednak nuli, 1, 2, 3 ili 4; R1 je vodik, cijano, formil, karboksil, halo, alkil, C2-6alkenil, C2-6alkinil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiltioalkil -C=N-OR11, amino, mono ili di(alkil)amino, aminoalkil, mono ili di(alkil)aminoalkil, alkilkarbonilaminoalkil, aminokarbonil, mono ili di(alkil)aminokarbonil, arilalkil, arilkarbonil, R5aR4aNalkil, di(aril)alkil, aril, R5aR4aN-, R5aR4aN-C(=O)- ili Het; R2 je vodik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino, pirolidino ili radikal formule pri čemu Y je CH2, O, S, NH ili N-alkil; R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, aril-aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; biciklo[2.2.1]heptil; Het; aril; ili -C(=NH)-NH2; iliR4 i R5 zajedno sa atomom dušika, na kojeg su vezani, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidin, piperazino, morfolino, 4-tiomorfolino, 1,1-dioksid-tiomorfolinil, azetidinil, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2,1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, aminoalkila, mono- ili dialkilaminoalkila, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila koji je proizvoljno supstituiran sa alkilom ili pirolidinilom koji je proizvoljno supstituiran sa arilalkilom; R4a i R5a zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila ili pirimidinila; R7 je vodik, halo, alkil, aril ili Het; R8 je
Claims (21)
1. Spoj, naznačen time, da je prikazan formulom (Ia) ili (Ib)
[image]
[image]
uključujući i bilo koji njegov stereokemijski izomerni oblik, pri čemu
p je cijeli broj koji je jednak 1, 2, 3 ili 4;
q je cijeli broj koji je jednak nuli, 1, 2, 3 ili 4;
R1 je vodik, cijano, formil, karboksil, halo, alkil, C2-6alkenil, C2-6alkinil, haloalkil, hidroksi, alkiloksi, alkiltio, alkiltioalkil -C=N-OR11, amino, mono ili di(alkil)amino, aminoalkil, mono ili di(alkil)aminoalkil, alkilkarbonilaminoalkil, aminokarbonil, mono ili di(alkil)aminokarbonil, arilalkil, arilkarbonil, R5aR4aNalkil, di(aril)alkil, aril, R5aR4aN-, R5aR4aN-C(=O)- ili Het;
R2 je vodik, alkiloksi, aril, ariloksi, hidroksi, merkapto, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino, pirolidino ili radikal formule
[image]
pri čemu Y je CH2, O, S, NH ili N-alkil;
R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, aril-aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili
[image]
R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; biciklo[2.2.1]heptil; Het; aril; ili -C(=NH)-NH2; ili
R4 i R5 zajedno sa atomom dušika, na kojeg su vezani, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidin, piperazino, morfolino, 4-tiomorfolino, 1,1-dioksid-tiomorfolinil, azetidinil, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2,1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, aminoalkila, mono- ili dialkilaminoalkila, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila koji je proizvoljno supstituiran sa alkilom ili pirolidinilom koji je proizvoljno supstituiran sa arilalkilom;
R4a i R5a zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1, 2, 3 ili 4 supstituenata, te je svaki supstituent nezavisno odabran od alkila, haloalkila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila ili pirimidinila;
R7 je vodik, halo, alkil, aril ili Het;
R8 je vodik ili alkil;
R9 je okso; ili
R8 i R9 zajedno tvore radikal -CH=CH-N=;
R11 je vodik ili alkil;
aril je homocikal koji je odabran od fenila, naftila, acenaftila ili tetrahidronaftila, te je svaki od njih proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, a svaki supstituent je nezavisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, C2-6alkenila koji je proizvoljno supstituiran sa fenilom, haloalkilom, alkiloksi, haloalkiloksi, karboksilom, alkiloksikarbonilom, aminokarbonilom, morfolinilom ili mono- ili dialkilaminokarbonilom;
Het je monociklički heterocikal koji je odabran iz N-fenoksipiperidinila, piperidinila, pirolila, pirazolila, imidazolila, furanila, tienila, oksazolila, izoksazolila, tiazolila, izotiazolila, piridinila, pirimidinila, pirazinila ili piridazinila; ili biciklički heterocikal koji je odabran od kvinolinila, kvinoksalinila, indolila, benzimidazolila, benzoksazolila, benzizoksazolila, benzotiazolila, benzizotiazolila, benzofuranila, benzotienila, 2,3-dihidrobenzo[1,4]dioksinila ili benzo[1,3]dioksolila; a svaki monociklički ili biciklički heterocikal je proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, te je svaki supstituent nezavisno odabran od halo, hidroksi, alkila ili alkiloksi;
njegov N-oksid, njegova farmaceutski prihvatljiva sol ili njegov solvat.
2. Spoj prema zahtjevu 1, naznačen time, da
R3 je alkil, arilalkil, aril-O-alkil, aril-alkil-O-alkil, aril, Het, Het-alkil, Het-O-alkil, Het-alkil-O-alkil ili
[image]
R4 i R5 svaki nezavisno je vodik; alkil; alkiloksialkil; arilalkil; Het-alkil; mono- ili dialkilaminoalkil; Het; aril; ili -C(=NH)-NH2; ili
R4 i R5 zajedno sa atomom dušika, na kojeg su spojeni, tvore radikal koji je odabran iz skupine koja sadrži pirolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 2,3-dihidroizoindol-1-il, tiazolidin-3-il, 1,2,3,6-tetrahidropiridil, heksahidro-1H-azepinil, heksahidro-1H-1,4-diazepinil, heksahidro-1,4-oksazepinil, 1,2,3,4-tetrahidroizokinolin-2-il, 2,5-diazabiciklo[2.2.1]heptil, pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piridinil, piridazinil, pirimidinil, pirazinil i triazinil, te je svaki radikal proizvoljno supstituiran sa 1,2, 3 ili 4 supstituenata, a svaki supstituent je nezavisno odabran od alkila, haloalkila, alkilkarbonila, halo, arilalkila, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiltioalkila, arila, piridila, pirimidinila, piperidinila ili pirolidinila koji je proizvoljno supstituiran sa arilalkilom;
aril je homocikal koji je odabran od fenila, naftila, acenaftila ili tetrahidronaftila, te je svaki od njih proizvoljno supstituiran sa 1, 2 ili 3 supstituenata, a svaki supstituent je nezavisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da alkil predstavlja C1-6alkil.
4. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R1 je halo, Het ili aril.
5. Spoj prema zahtjevu 4, naznačen time, da R1 je halo.
6. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je p jednako 1.
7. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R2 je C1-6alkiloksi.
8. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R3 je aril.
9. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da je q jednako 2, 3 ili 4.
10. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R4 i R5 predstavljaju C1-6alkil.
11. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da R7 je vodik.
12. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da navedeni spoj je spoj formule (Ia).
13. Spoj prema zahtjevu 12, naznačen time, da R1 je halo; R2 je C1-6alkiloksi; R8 je aril; R4 i R5 su C1-6alkil; R7 je vodik; q je 2, 3 ili 4; te p je 1.
14. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, da se navedeni spoj upotrebljava kao lijek.
15. Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se navedeni spoj upotrebljava kao lijek za liječenje bakterijske infekcije uključujući i mikobakterijsku infekciju.
16. Farmaceutski pripravak, naznačen time, da sadrži farmaceutski prihvatljivi nosač, te kao aktivan sastojak, terapeutski učinkovitu količinu spoja kako je definirano u bilo kojem od zahtjeva 1 do 13.
17. Spoj prema zahtjevu 15, naznačen time, da navedena bakterijska infekcija je infekcija sa gram-pozitivnom bakterijom.
18. Spoj prema zahtjevu 15, naznačen time, da navedena gram-pozitivna bakterija je Streptococcus pneumoniae ili Staphilococcus aureus.
19. Kombinacija, naznačena time, da sadrži (a) spoj prema bilo kojem od zahtjeva od 1 do 13 i (b) jedno ili više drugih antibakterijskih sredstava.
20. Produkt, naznačen time, da sadrži (a) spoj prema bilo kojem od zahtjeva od 1 do 13 i (b) jedno ili više drugih antibakterijskih sredstava, u obliku kombiniranog pripravka za simultanu, odvojenu ili sekvencijalnu upotrebu kod liječenja bakterijske infekcije.
21. Spoj prema zahtjevu 18, naznačen time, da je navedena gram-pozitivna bakterija Staphilococcus aureus koji je otporan na meticilin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125529 | 2006-12-06 | ||
| PCT/EP2007/063316 WO2008068270A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110540T1 true HRP20110540T1 (hr) | 2011-08-31 |
Family
ID=38124123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110540T HRP20110540T1 (hr) | 2006-12-06 | 2007-12-04 | Antibakterijski derivati kinolina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20110166179A1 (hr) |
| EP (1) | EP2099759B1 (hr) |
| JP (1) | JP5356246B2 (hr) |
| KR (1) | KR101526175B1 (hr) |
| CN (1) | CN101553471B (hr) |
| AR (1) | AR064152A1 (hr) |
| AT (1) | ATE509915T1 (hr) |
| AU (1) | AU2007328890B2 (hr) |
| BR (1) | BRPI0720133A2 (hr) |
| CA (1) | CA2669829C (hr) |
| CL (1) | CL2007003517A1 (hr) |
| CY (1) | CY1112230T1 (hr) |
| DK (1) | DK2099759T3 (hr) |
| ES (1) | ES2366062T3 (hr) |
| HR (1) | HRP20110540T1 (hr) |
| IL (1) | IL199084A0 (hr) |
| JO (1) | JO2725B1 (hr) |
| ME (1) | ME01245B (hr) |
| MX (1) | MX2009005981A (hr) |
| NO (1) | NO342774B1 (hr) |
| NZ (1) | NZ577069A (hr) |
| PL (1) | PL2099759T3 (hr) |
| PT (1) | PT2099759E (hr) |
| RS (1) | RS51848B (hr) |
| RU (1) | RU2439058C2 (hr) |
| SI (1) | SI2099759T1 (hr) |
| TW (1) | TWI487525B (hr) |
| WO (1) | WO2008068270A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2786089C (en) * | 2010-01-04 | 2014-04-15 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and agricultural fungicide |
| AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| CA2869453C (en) | 2012-04-27 | 2021-03-02 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| PL2841425T3 (pl) | 2012-04-27 | 2016-10-31 | Antybakteryjne pochodne chinoliny | |
| CN105232540A (zh) * | 2015-09-29 | 2016-01-13 | 王洪燕 | 一种治疗烧伤后感染的药物组合物 |
| EP4493551A1 (en) | 2022-03-14 | 2025-01-22 | Slap Pharmaceuticals LLC | Multicyclic compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526265A (ja) * | 1997-12-22 | 2001-12-18 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド |
| EP1527050B1 (en) * | 2002-07-25 | 2010-04-07 | Janssen Pharmaceutica N.V. | Quinoline derivatives and their use as mycobacterial inhibitors |
| DK1711181T3 (da) * | 2004-01-23 | 2010-02-01 | Janssen Pharmaceutica Nv | Quinolin-derivater og anvendelse af disse som mycobakterielle inhibitorer |
| PT1753427E (pt) * | 2004-05-28 | 2008-07-04 | Janssen Pharmaceutica Nv | Utilização de derivados quinolina substituídos para o tratamento de doenças micobacterianas resistentes a fármacos |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
-
2007
- 2007-11-29 JO JO2007506A patent/JO2725B1/en active
- 2007-12-04 AT AT07847814T patent/ATE509915T1/de active
- 2007-12-04 JP JP2009539741A patent/JP5356246B2/ja not_active Expired - Fee Related
- 2007-12-04 NZ NZ577069A patent/NZ577069A/en not_active IP Right Cessation
- 2007-12-04 RS RS20110354A patent/RS51848B/en unknown
- 2007-12-04 HR HR20110540T patent/HRP20110540T1/hr unknown
- 2007-12-04 PL PL07847814T patent/PL2099759T3/pl unknown
- 2007-12-04 PT PT07847814T patent/PT2099759E/pt unknown
- 2007-12-04 DK DK07847814.6T patent/DK2099759T3/da active
- 2007-12-04 CA CA2669829A patent/CA2669829C/en active Active
- 2007-12-04 SI SI200730665T patent/SI2099759T1/sl unknown
- 2007-12-04 AU AU2007328890A patent/AU2007328890B2/en not_active Ceased
- 2007-12-04 BR BRPI0720133-8A patent/BRPI0720133A2/pt not_active Application Discontinuation
- 2007-12-04 RU RU2009125520/04A patent/RU2439058C2/ru active
- 2007-12-04 ME MEP-2011-141A patent/ME01245B/me unknown
- 2007-12-04 WO PCT/EP2007/063316 patent/WO2008068270A1/en active Application Filing
- 2007-12-04 KR KR1020097013237A patent/KR101526175B1/ko not_active Expired - Fee Related
- 2007-12-04 MX MX2009005981A patent/MX2009005981A/es active IP Right Grant
- 2007-12-04 EP EP07847814A patent/EP2099759B1/en active Active
- 2007-12-04 ES ES07847814T patent/ES2366062T3/es active Active
- 2007-12-04 US US12/516,396 patent/US20110166179A1/en not_active Abandoned
- 2007-12-04 CN CN2007800454055A patent/CN101553471B/zh not_active Expired - Fee Related
- 2007-12-05 TW TW096146211A patent/TWI487525B/zh not_active IP Right Cessation
- 2007-12-05 CL CL200703517A patent/CL2007003517A1/es unknown
- 2007-12-05 AR ARP070105445A patent/AR064152A1/es unknown
-
2009
- 2009-06-02 IL IL199084A patent/IL199084A0/en active IP Right Grant
- 2009-07-06 NO NO20092547A patent/NO342774B1/no unknown
-
2011
- 2011-08-10 CY CY20111100772T patent/CY1112230T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20100428T1 (hr) | Antibakterijski derivati kvinolina | |
| HRP20110540T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2010511667A5 (hr) | ||
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| MX2009007006A (es) | Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana. | |
| HRP20080307T3 (hr) | Uporaba supstituiranih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lijekove | |
| HRP20110392T1 (hr) | Derivati kinolina za liječenje latentne tuberkuloze | |
| HRP20230657T1 (hr) | Spojevi i pripravci za liječenje hematoloških poremećaja | |
| RS52431B (en) | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | |
| AR054587A1 (es) | Derivados de quinolina antibacterianos | |
| HRP20160252T1 (hr) | C-4" položaj supstituiranog derivata makrolida | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20151111T1 (hr) | Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora | |
| JP2010511671A5 (hr) | ||
| HRP20100384T1 (hr) | Antibakterijski derivati kvinolina | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20170044T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2010511670A5 (hr) | ||
| HRP20110024T1 (hr) | Antibakterijski derivati kvinolina | |
| MX2009003051A (es) | Derivados de quinolinona. | |
| HRP20120912T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| AR064147A1 (es) | Derivados de quinolina antibacterianos | |
| HRP20161704T1 (hr) | Derivati kinolina kao antibakterijska sredstva |